Transgene
ALTRO.PADrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
MVA-MUC1-IL2
Carcinoma, Non-Small-Cell Lung
TG4050
Squamous Cell Carcinoma of Head and Neck
TG4001
HPV-Related Carcinoma
TG4010
Non Small Cell Lung Cancer Metastatic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MVA-MUC1-IL2 | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
TG4050 | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
TG4001 | Phase 2 | HPV-Related Carcinoma | - | - |
TG4010 | Phase 2 | Non Small Cell Lung Cancer Metastatic | - | - |
Frequently asked questions
What is in Transgene's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Transgene's (ALTRO.PA) pipeline across Phase 3, Phase 2. Its lead program is MVA-MUC1-IL2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Transgene's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Transgene (ALTRO.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALTRO.PA biotech catalysts?→
Add ALTRO.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Transgene's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.